NATCOPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.1
| Stock Code | NATCOPHARM | Market Cap | 21,028 Cr. | Current Price | 1,175 ₹ | High / Low | 1,227 ₹ |
| Stock P/E | 14.0 | Book Value | 462 ₹ | Dividend Yield | 0.51 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,094 ₹ | DMA 200 | 982 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 58.3 | MACD | 26.1 | Volume | 3,53,935 | Avg Vol 1Wk | 3,55,969 |
| Low price | 789 ₹ | High price | 1,227 ₹ | PEG Ratio | 0.09 | Debt to equity | 0.03 |
| 52w Index | 88.2 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 31.6 |
📊 Analysis: NATCOPHARM shows strong intraday potential. Current price (₹1,175) is well above DMA 50 (₹1,094) and DMA 200 (₹982), reflecting bullish momentum. RSI at 58.3 indicates healthy strength without being overbought, while MACD (26.1) confirms positive bias. Volume (3.53L) is in line with average (3.55L), ensuring liquidity. Despite strong technicals, quarterly PAT dropped sharply (₹501 Cr → ₹107 Cr), raising caution on earnings consistency.
💹 Optimal Buy Price: ₹1,170–1,180 if sustained above VWAP with strong volume.
🎯 Profit Exit Levels: ₹1,195 (recent resistance) and ₹1,210–1,220 (next resistance zone).
🛑 Stop-Loss: ₹1,155 (below intraday support).
⏱️ If Already Holding: Exit near ₹1,195–1,220 if momentum slows or RSI approaches 65 intraday. Cut positions if price breaks below ₹1,155 with rising volume pressure.
Positive
- Strong ROE (27.5%) and ROCE (31.8%) highlight robust fundamentals.
- PEG ratio at 0.09 suggests excellent growth potential at current valuations.
- Debt-to-equity ratio at 0.03 indicates very low leverage.
- FII holding increased (+2.21%), showing strong foreign investor confidence.
Limitation
- Quarterly PAT dropped sharply (₹501 Cr → ₹107 Cr), raising earnings concerns.
- Dividend yield modest at 0.51%.
- DII holding only marginally increased (+0.07%).
Company Negative News
- Sharp decline in quarterly profits raises concerns about earnings stability.
- Volatility in earnings may affect short-term sentiment.
Company Positive News
- Strong institutional investor confidence with significant FII inflows (+2.21%).
- Attractive valuations compared to industry peers.
Industry
- Industry P/E at 31.6, much higher than NATCOPHARM’s 14.0, suggesting undervaluation relative to peers.
- Pharma sector remains resilient with long-term demand drivers despite earnings volatility.
Conclusion
⚖️ NATCOPHARM offers strong intraday trading potential with bullish technicals and undervaluation relative to peers. Suitable for trades above ₹1,170 with profit targets near ₹1,195–1,220 and strict stop-loss at ₹1,155. Momentum indicators suggest caution as earnings volatility persists.
Would you like me to extend this into a swing trade analysis with 1–2 week holding logic, or keep it strictly intraday-focused?